Prevalence of thrombotic risk factors among β-thalassemia patients from Western Iran

Journal of Thrombosis and Thrombolysis

Volumn 26, Issue 3, 2008, Pages 229-233

  Rahimi, Zohreh ^a,b   Ghaderi, Mandana ^b   Nagel, Ronald L ^c   Muniz, Adriana ^c  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Thalassemia; Factor V Leiden; Iran; MTHFR; Prothrombin G20210A

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PROTHROMBIN;

ADOLESCENT; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; IRAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SPLENECTOMY; THALASSEMIA MAJOR; THALASSEMIA MINOR; THROMBOEMBOLISM;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FACTOR V; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; IRAN; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; PROTHROMBIN; THROMBOPHILIA; YOUNG ADULT;

EID: 56349152011     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-007-0163-0     Document Type: Article

References (17)

1. Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E (2004) Thalassemia. Hematology. Am Soc Hematol Educ Program 1:14-34
2. Eldor A, Durst R, Hy-Am E, Goldfarb A, Gillis S, Rachmilewitz EA, Abramov A, Maclouf J, Godefray YC, De Raucourt E, Guillin MC (1999) A chronic hypercoagulable state in patients with β-thalassaemia major is already present in childhood. Br J Haematol 107:739-746
3. Cappellini MD, Grespi E, Cassinerio E, Bignamini D, Fiorelli G (2005) Coagulation and splenectomy: An overview. Ann NY Acad Sci 1054:317-324
4. Moratelli S, De Sanctis V, Gemmati D, Serino ML, Mari R, Gamberini MR, Scapoli GL (1998) Thrombotic risk in thalassemic patients. J Pediatr Endocrinol Metab 11:915-921
5. Panigrahi I, Agarwal S (2007) Thromboembolic complications in β-thalassemia: Beyond the horizon. Thromb Res 120:783-789
6. Borgna-Pignatti C, Carnelli V, Caruso V, Dore F, De Mattia D, Di Palma A, Di Gregorio F, Romeo MA, Longhi R, Mangiagli A, Melevendi C, Pizzarelli G, Musumeci S (1998) Thromboembolic events in beta thalassemia major: An Italian multicenter study. Acta Haematol 99:76-79
7. Zalloua PA, Shbakio H, Mourad YA, Koussa S, Taher A (2003) Incidence of thromboembolic events in Lebanese thalassemia intermedia patients. Thromb Haemost 89:767-768
8. Kahn JE, Veyssier-Belot C, Renier JL, de Mazancourt P, Peltier JY, de Raucourt E (2002) Recurrent thromboembolism in a patient with β-thalassemia major associated with double heterozygosity for factor V R506Q and prothrombin G20210A mutations. Blood Coagul Fibrinolysis 13:461-463
9. Brankovic-Sreckovic V, Milic Rasic V, Djordjevic V, Kuzmanovic M, Pavlovic S (2007) Arterial ischemic stroke in a child with β-thalassemia trait and methylentetrahydrofolate reductase mutation. J Child Neurol. 22:208-210
10. Rahimi Z, Vaisi Raygani A, Merat A, Haghshenass M, Gerard N, Nagel RL, Krishnamoorthy R (2006) Thalassemic mutations in Southern Iran. Ir J Med Sci 31:70-73
11. Rahimi Z, Vaisi-Raygani A, Mozafari H, Kharrazi H, Rezaei M, Nagel RL (2007) Prevalence of factor V Leiden (G1691A) and prothrombin (G20210A) among Kurdish population from Western Iran. J Thromb Thrombolys (in press)
12. Old JM, Higgs DR (1983) Gene analysis. In: Weatherall DJ (ed) Methods in hematology. The thalassemias, vol 6. Churchill Livingstone, London, pp 74-101
13. Rahimi Z, Vaisi-Raygani A, Nagel RL, Muniz A (2007) Thrombophilic mutations among Southern Iranian patients with sickle cell disease: High prevalence of factor V Leiden. J Thromb Thrombolysis (in press)
14. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, Rozen R (1995) A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111-113
15. Taher A, Isma'eel H, Mehio G, Bignamini D, Kattamis A, Rachmilewitz EA, Cappellini MD (2006) Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost 96:488-491
16. Tripatara A, Jetsrisuparb A, Teeratakulpisarn J, Kuaha K (2007) Hemostatic alterations in splenectomized and non-splenectomized patients with β- thalassaemia/hemoglobin E disease. Thromb Res (in press)
17. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT, Raghunathan TE, Koepsell TD, Reitsma PH (1997) Factor V Leiden (Resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 89:2817-2821